Applying to Clinical Trial: Pharmacokinetic (PK) and Safety Study of Iptacopan (LNP023) in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Matched Control Healthy Participants With Normal Hepatic Function.

Contact this trialFirst, we need to learn more about you.

Complement Inhibitor

Iptacopan for Liver disease

Recruiting1 awardPhase 1

San Antonio, Texas

This trial tested a medication called iptacopan to see how it behaves in people with various levels of liver function. They wanted to understand how the drug is absorbed, distributed, and eliminated from the body.

Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.

We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our and .

Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.

By clicking start, you agree to our